Bionano Genomics (BNGO) Receivables - Net (2017 - 2026)

Bionano Genomics has disclosed Receivables - Net across 10 years of filings, most recently posting $4.2 million for Q1 2026.

• Receivables - Net for Q1 2026 came in at $4.2 million, up 23.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (up 23.76% YoY), and the FY2025 annual result was $5.2 million, up 9.81% from the prior year.
• Receivables - Net came in at $4.2 million for Q1 2026 at Bionano Genomics, down from $5.2 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $9.3 million in Q4 2023 to a low of $3.4 million in Q1 2025.
• The 5-year median for Receivables - Net is $6.0 million (2022), against an average of $6.1 million.
• Across the five-year window, Receivables - Net surged 46.39% in 2022 and tumbled 59.65% in 2025, its largest moves.
• Bionano Genomics' Receivables - Net stood at $7.0 million in 2022, then soared by 32.71% to $9.3 million in 2023, then plunged by 47.32% to $4.9 million in 2024, then climbed by 6.29% to $5.2 million in 2025, then fell by 20.45% to $4.2 million in 2026.
• The last three Receivables - Net figures came in at $4.2 million (Q1 2026), $5.2 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.